NCT03384641View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

January 13, 2023

Study Completion Date

January 9, 2024

Conditions
Leprosy, Multibacillary
Interventions
DRUG

Bedaquiline 200 mg

Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.

Trial Locations (2)

17034-971

Instituto Lauro de Souza Lima, Bauru

69065-130

Fundacao Hospitalar de Dermatologia Tropical e Venereologia Alfredo da Matta - FUHAM, Manaus

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03384641 - A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy | Biotech Hunter | Biotech Hunter